| Literature DB >> 31331245 |
Kelly E Ormond1, Yvonne Bombard2,3, Vence L Bonham4, Lily Hoffman-Andrews5, Heidi Howard6,7, Rosario Isasi8, Kiran Musunuru9, Kirsten A Riggan10, Marsha Michie11, Megan Allyse12.
Abstract
Gene-editing techniques have progressed rapidly in the past 5 years. There are already ongoing human somatic gene-editing clinical trials for multiple diseases. And there has been one purported scenario of human germline gene editing in late 2018. In this paper, we will review the current state of the technology, discuss the ethical and social issues that surround the various forms of gene editing, as well as review emerging stakeholder data from professionals, the 'general public' and individuals and families dealing with genetic diseases potentially treatable by gene editing.Entities:
Keywords: CRISPR; clinical trials; ethics; gene editing; genome editing; germline gene editing; professional attitudes; public attitudes; somatic gene editing; stakeholder research
Mesh:
Year: 2019 PMID: 31331245 DOI: 10.2217/pme-2018-0155
Source DB: PubMed Journal: Per Med ISSN: 1741-0541 Impact factor: 2.512